An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to- moderate persistent asthma
Patients with mild asthma may benefit from increasing their inhaled corticosteroid dose, adding a tong-acting beta(2)-agonist, or both. This study assessed the cost-effectiveness of these options. Patients aged greater than or equal to12 years with mild-to-moderate persistent asthma (n = 1272) were randomised to twice-daily, double-blind treatment with budesonide 100 mug, budesonide 100 mug plus f
